Literature DB >> 1322070

Drug resistance in leishmaniasis: its implication in systemic chemotherapy of cutaneous and mucocutaneous disease.

M Grogl1, T N Thomason, E D Franke.   

Abstract

We report that in vitro sensitivity to pentavalent antimony (Sb5) of 35 Leishmania isolates as determined by the semiautomated microdilution technique (SAMT) showed an 89% and 86% correlation with clinical outcome after Pentostam and Glucantime treatment, respectively. These results suggest that in over 85% of the cases, the clinical outcome of treatment (cure or failure) could have been predicted by using the SAMT technique. Furthermore, the results clearly indicate that drug resistance is a problem, and that at least in some instances, failure to respond to treatment is due to the parasite as well as patient factors. Strains from Sb5-treated patients with American cutaneous and mucocutaneous disease who fail at least one complete course of Pentostam are as highly nonresponsive to this drug as laboratory-proven drug-resistant Leishmania strains. It was determined that some Leishmania isolates are innately less susceptible to Sb5 than others, and that moderate resistance to Sb5 exists in nature. A 10- and 17-fold increase was detected in the 50% inhibitory concentration (IC50) of Sb5 for L. mexicana and L. braziliensis isolates after subcurative treatment of the patients, when compared with the mean IC50 of seven and six isolates from the same endemic areas in Guatemala and Peru, respectively. Thus, we have correlated subcurative treatment to a decrease in drug sensitivity in at least these two cases. Collectively, these results indicate that under Sb5 pressure from undermedication, the parasites inherently most drug resistant are favored. The degree of resistance of a strain to antimony in association with host-specific factors will determine whether the clinical response to treatment with this drug is a total cure or a partial response followed by relapse(s), and possibly secondary unresponsiveness resulting in total resistance to antimony. It is evident from our in vitro test data that the SAMT is an extremely powerful and highly accurate technique for the prediction and determination of drug sensitivity of leishmanial isolates, as well as a means to screen for anti-leishmanial agents.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1322070     DOI: 10.4269/ajtmh.1992.47.117

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  50 in total

1.  Pathways of As(III) detoxification in Saccharomyces cerevisiae.

Authors:  M Ghosh; J Shen; B P Rosen
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-27       Impact factor: 11.205

2.  In vitro activities of iboga alkaloid congeners coronaridine and 18-methoxycoronaridine against Leishmania amazonensis.

Authors:  Jan Carlo Delorenzi; Leonardo Freire-de-Lima; Cerli R Gattass; Deise de Andrade Costa; Liwen He; Martin E Kuehne; Elvira M B Saraiva
Journal:  Antimicrob Agents Chemother       Date:  2002-07       Impact factor: 5.191

3.  Use of an attenuated leishmanial parasite as an immunoprophylactic and immunotherapeutic agent against murine visceral leishmaniasis.

Authors:  S Mukhopadhyay; S Bhattacharyya; R Majhi; T De; K Naskar; S Majumdar; S Roy
Journal:  Clin Diagn Lab Immunol       Date:  2000-03

4.  UDP-Gal: N-acetylglucosamine beta 1-4 galactosyltransferase expressing live attenuated parasites as vaccine for visceral leishmaniasis.

Authors:  Siddhartha Kumar Bhaumik; Manoj Kumar Singh; Subir Karmakar; Tripti De
Journal:  Glycoconj J       Date:  2008-11-13       Impact factor: 2.916

Review 5.  ABC proteins of Leishmania.

Authors:  D Légaré; S Cayer; A K Singh; D Richard; B Papadopoulou; M Ouellette
Journal:  J Bioenerg Biomembr       Date:  2001-12       Impact factor: 2.945

6.  An axenic amastigote system for drug screening.

Authors:  H L Callahan; A C Portal; R Devereaux; M Grogl
Journal:  Antimicrob Agents Chemother       Date:  1997-04       Impact factor: 5.191

7.  Immunological determinants of clinical outcome in Peruvian patients with tegumentary leishmaniasis treated with pentavalent antimonials.

Authors:  Anne Maurer-Cecchini; Saskia Decuypere; François Chappuis; Coralie Alexandrenne; Simonne De Doncker; Marleen Boelaert; Jean-Claude Dujardin; Louis Loutan; Jean-Michel Dayer; Gianfranco Tulliano; Jorge Arevalo; Alexandro Llanos-Cuentas; Carlo Chizzolini
Journal:  Infect Immun       Date:  2009-02-23       Impact factor: 3.441

8.  Molecular Docking and in Vitro Antileishmanial Evaluation of Chromene-2-thione Analogues.

Authors:  Rajiv Kumar Verma; Vijay Kumar Prajapati; Girijesh Kumar Verma; Deblina Chakraborty; Shyam Sundar; Madhukar Rai; Vikash Kumar Dubey; Maya Shankar Singh
Journal:  ACS Med Chem Lett       Date:  2012-01-18       Impact factor: 4.345

9.  Protein network prediction and topological analysis in Leishmania major as a tool for drug target selection.

Authors:  Andrés F Flórez; Daeui Park; Jong Bhak; Byoung-Chul Kim; Allan Kuchinsky; John H Morris; Jairo Espinosa; Carlos Muskus
Journal:  BMC Bioinformatics       Date:  2010-09-27       Impact factor: 3.169

Review 10.  Human antiprotozoal therapy: past, present, and future.

Authors:  M Khaw; C B Panosian
Journal:  Clin Microbiol Rev       Date:  1995-07       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.